Journal of Clinical Oncology, Vol 24, No 15 (May 20), 2006: pp. 2283-2289
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.04.5716
Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4
Kimberly E. Beck,
Joseph A. Blansfield,
Khoi Q. Tran,
Andrew L. Feldman,
Marybeth S. Hughes,
Richard E. Royal,
Udai S. Kammula,
Suzanne L. Topalian,
Richard M. Sherry,
David Kleiner,
Martha Quezado,
Israel Lowy,
Michael Yellin,
Steven A. Rosenberg,
James C. Yang
From the Surgery Branch and Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD; and Medarex Inc, Princeton NJ
Address reprint requests to James C. Yang, MD, Surgery Branch, National Cancer Institute, National Institutes of Health, CRC, Room 3W, 10 Center Dr, Bethesda, MD 20892-1201; e-mail: James_Yang{at}nih.gov
Purpose Cytotoxic T-lymphocyte–associated antigen 4 (CTLA4) is an inhibitory receptor on T cells. Knocking out CTLA4 in mice causes lethal lymphoproliferation, and polymorphisms in human CTLA4 are associated with autoimmune disease. Trials of the anti-CTLA4 antibody ipilimumab (MDX-010) have resulted in durable cancer regression and immune-mediated toxicities. A report on the diagnosis, pathology, treatment, clinical outcome, and significance of the immune-mediated enterocolitis seen with ipilimumab is presented.
Patients and Methods We treated 198 patients with metastatic melanoma (MM) or renal cell carcinoma (RCC) with ipilimumab.
Results The overall objective tumor response rate was 14%. We observed several immune mediated toxicities including dermatitis, enterocolitis, hypophysitis, uveitis, hepatitis, and nephritis. Enterocolitis, defined by grade 3/4 clinical presentation and/or biopsy documentation, was the most common major toxicity (21% of patients). It presented with diarrhea, and biopsies showed both neutrophilic and lymphocytic inflammation. Most patients who developed enterocolitis responded to high-dose systemic corticosteroids. There was no evidence that steroid administration affected tumor responses. Five patients developed perforation or required colectomy. Four other patients with steroid-refractory enterocolitis appeared to respond promptly to tumor necrosis factor alpha blockade with infliximab. Objective tumor response rates in patients with enterocolitis were 36% for MM and 35% for RCC, compared with 11% and 2% in patients without enterocolitis, respectively (P = .0065 for MM and P = .0016 for RCC).
Conclusion CTLA4 seems to be a significant component of tolerance to tumor and in protection against immune mediated enterocolitis and these phenomena are significantly associated in cancer patients.
Supported in part by the Intramural Research Program of the National Cancer Institute, National Institutes of Health.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
Related Editorial
- Is Tumor Immunity the Same Thing As Autoimmunity? Implications for Cancer Immunotherapy
Howard L. Kaufman and Jedd D. Wolchok
JCO 2006 24: 2230-2232
[Full Text]
Related Correspondence
- Does CTLA4 Influence the Suppressive Effect of CD25+CD4+ Regulatory T Cells?
Gianluigi Ferretti, Alessandra Felici, Maria Simona Pino, and Francesco Cognetti
JCO 2006 24: 5469-5470
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
J. Weber, J. A. Thompson, O. Hamid, D. Minor, A. Amin, I. Ron, R. Ridolfi, H. Assi, A. Maraveyas, D. Berman, et al.
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Clin. Cancer Res.,
September 1, 2009;
15(17):
5591 - 5598.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Jolly, M. R. Clatworthy, C. Lawrence, P. D. Nathan, and K. Farrington
Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
NDT Plus,
August 1, 2009;
2(4):
300 - 302.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Schadendorf, S. M. Algarra, L. Bastholt, G. Cinat, B. Dreno, A. M. M. Eggermont, E. Espinosa, J. Guo, A. Hauschild, T. Petrella, et al.
Immunotherapy of distant metastatic disease
Ann. Onc.,
August 1, 2009;
20(suppl_6):
vi41 - vi50.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Robert and F. Ghiringhelli
What Is the Role of Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?
Oncologist,
August 1, 2009;
14(8):
848 - 861.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Fadel, K. E. Karoui, and B. Knebelmann
Anti-CTLA4 Antibody-Induced Lupus Nephritis
N. Engl. J. Med.,
July 9, 2009;
361(2):
211 - 212.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Rapoport, E. A. Stadtmauer, N. Aqui, D. Vogl, A. Chew, H.-B. Fang, S. Janofsky, K. Yager, E. Veloso, Z. Zheng, et al.
Rapid Immune Recovery and Graft-versus-Host Disease-like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells
Clin. Cancer Res.,
July 1, 2009;
15(13):
4499 - 4507.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Houot and R. Levy
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy
Blood,
April 9, 2009;
113(15):
3546 - 3552.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Klein, L. M. Ebert, T. Nicholaou, J. Browning, S. E. Russell, M. Zuber, H. M. Jackson, N. Dimopoulos, B. S. Tan, A. Hoos, et al.
Melan-A-specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4
Clin. Cancer Res.,
April 1, 2009;
15(7):
2507 - 2513.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Bashey, B. Medina, S. Corringham, M. Pasek, E. Carrier, L. Vrooman, I. Lowy, S. R. Solomon, L. E. Morris, H. K. Holland, et al.
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
Blood,
February 12, 2009;
113(7):
1581 - 1588.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Fong, S. S. Kwek, S. O'Brien, B. Kavanagh, D. G. McNeel, V. Weinberg, A. M. Lin, J. Rosenberg, C. J. Ryan, B. I. Rini, et al.
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
Cancer Res.,
January 15, 2009;
69(2):
609 - 615.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Weber, S. O'Day, W. Urba, J. Powderly, G. Nichol, M. Yellin, J. Snively, and E. Hersh
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
J. Clin. Oncol.,
December 20, 2008;
26(36):
5950 - 5956.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Poust
Targeting metastatic melanoma
Am. J. Health Syst. Pharm.,
December 15, 2008;
65(24_Supplement_9):
S9 - S15.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Fong and E. J. Small
Anti-Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
J. Clin. Oncol.,
November 10, 2008;
26(32):
5275 - 5283.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Wolchok and Y. Saenger
The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
Oncologist,
October 1, 2008;
13(suppl_4):
2 - 9.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Weber
Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010)
Oncologist,
October 1, 2008;
13(suppl_4):
16 - 25.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Kavanagh, S. O'Brien, D. Lee, Y. Hou, V. Weinberg, B. Rini, J. P. Allison, E. J. Small, and L. Fong
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
Blood,
August 15, 2008;
112(4):
1175 - 1183.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. S. Hodi, M. Butler, D. A. Oble, M. V. Seiden, F. G. Haluska, A. Kruse, S. MacRae, M. Nelson, C. Canning, I. Lowy, et al.
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
PNAS,
February 26, 2008;
105(8):
3005 - 3010.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Tsatsanis, K. Vaporidi, V. Zacharioudaki, A. Androulidaki, Y. Sykulev, A. N. Margioris, and P. N. Tsichlis
Tpl2 and ERK transduce antiproliferative T cell receptor signals and inhibit transformation of chronically stimulated T cells
PNAS,
February 26, 2008;
105(8):
2987 - 2992.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. G. Downey, J. A. Klapper, F. O. Smith, J. C. Yang, R. M. Sherry, R. E. Royal, U. S. Kammula, M. S. Hughes, T. E. Allen, C. L. Levy, et al.
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Clin. Cancer Res.,
November 15, 2007;
13(22):
6681 - 6688.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell
Transforming Growth Factor-{beta} and the Immune Response: Implications for Anticancer Therapy
Clin. Cancer Res.,
September 15, 2007;
13(18):
5262 - 5270.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Zang and J. P. Allison
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
Clin. Cancer Res.,
September 15, 2007;
13(18):
5271 - 5279.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Ahuja, C. A. Estrada, and M. L. Lindsey
Crosstalk Between Cytotoxic T-Lymphocyte Associated Antigen-4 and Interleukin-12 in Cytotoxic T-Lymphocyte Mediated Myocarditis: Adding Another Link to the Chain
Circ. Res.,
August 3, 2007;
101(3):
218 - 220.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Weber
Review: Anti CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events
Oncologist,
July 1, 2007;
12(7):
864 - 872.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ribas, D. C. Hanson, D. A. Noe, R. Millham, D. J. Guyot, S. H. Bernstein, P. C. Canniff, A. Sharma, and J. Gomez-Navarro
Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer
Oncologist,
July 1, 2007;
12(7):
873 - 883.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. J. Small, N. S. Tchekmedyian, B. I. Rini, L. Fong, I. Lowy, and J. P. Allison
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
Clin. Cancer Res.,
March 15, 2007;
13(6):
1810 - 1815.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. O'Mahony, J. C. Morris, C. Quinn, W. Gao, W. H. Wilson, B. Gause, S. Pittaluga, S. Neelapu, M. Brown, T. A. Fleisher, et al.
A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy
Clin. Cancer Res.,
February 1, 2007;
13(3):
958 - 964.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Yang and R. Childs
Immunotherapy for Renal Cell Cancer
J. Clin. Oncol.,
December 10, 2006;
24(35):
5576 - 5583.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Yang
In Reply
J. Clin. Oncol.,
December 1, 2006;
24(34):
5470 - 5471.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Ferretti, A. Felici, M. S. Pino, and F. Cognetti
Does CTLA4 Influence the Suppressive Effect of CD25+CD4+ Regulatory T Cells?
J. Clin. Oncol.,
December 1, 2006;
24(34):
5469 - 5470.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. L. Kaufman and J. D. Wolchok
Is Tumor Immunity the Same Thing As Autoimmunity? Implications for Cancer Immunotherapy
J. Clin. Oncol.,
May 20, 2006;
24(15):
2230 - 2232.
[Full Text]
[PDF]
|
 |
|
|